Alirocumab
CAS 1245916-14-6 2 FDA-DMF suppliersBiologic
Overview
Alirocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), used to lower cholesterol levels in the blood. It is primarily prescribed to patients with hypercholesterolemia who require additional lipid-lowering treatment and are intolerant or unresponsive to statins.
Therapeutic areas
CardiovascularLipid metabolism disordersHyperlipidemia
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.